Literature DB >> 6256045

Labetalol: potent antihypertensive agent that blocks both alpha- and beta-adrenergic receptors.

B J Milne, A G Logan.   

Abstract

Labetalol was administered as the sole antihypertensive agent to 20 ambulatory patients with mild to moderate hypertension. The mean systolic and diastolic blood pressures (+/- standard error of the mean) with the patients sitting fell significantly (P < 0.001), from 145.5 +/- 3.2 and 103.7 +/- 1.6 mm Hg respectively at the start of labetalol therapy (after a period free of antihypertensive medication) to 125.7 +/- 2.0 and 87.2 +/- 1.1 mm Hg by the end of the trial. The diastolic blood pressure was well controlled (90 mm Hg or less) with labetalol therapy in 90% of the patients. The medication was well tolerated, and no orthostatic fall in the diastolic blood pressure was observed. Pharmacologically labetalol most closely resembles a combination of a nonselective beta-adrenergic blocker like propranolol and a postsynaptic alpha-adrenergic blocker like prazosin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6256045      PMCID: PMC1704976     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  7 in total

1.  Antihypertensive effect and tolerability of metoprolol during long-term treatment: a multicentre study.

Authors:  S Rosengard
Journal:  J Int Med Res       Date:  1977       Impact factor: 1.671

2.  Differences between presynaptic and postsynaptic alpha-adrenoceptors in the isolated nictitating membrane of the cat: effects of metanephrine and tolazoline.

Authors:  S Arbilla; S Z Langer
Journal:  Br J Pharmacol       Date:  1978-10       Impact factor: 8.739

3.  Alpha and beta adrenergic blockade in hypertension.

Authors:  L J Beilin; B E Juel-Jensen
Journal:  Lancet       Date:  1972-05-06       Impact factor: 79.321

4.  Detection of 'responders' to long-term pindolol therapy from phasic changes in cardiovascular function during acute intravenous administration in essential hypertension.

Authors:  A G Logan; B J Milne; J M Colman
Journal:  Clin Invest Med       Date:  1978       Impact factor: 0.825

5.  Effect of nadolol in treatment of hypertension.

Authors:  L Volicer; C S Liang; H Gavras; C P Tifft; G R Kershaw; I Gavras; D L Griffith; R Vukovitch; H R Brunner
Journal:  J Clin Pharmacol       Date:  1979 Feb-Mar       Impact factor: 3.126

6.  The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen.

Authors:  A G Blakeley; R J Summers
Journal:  Br J Pharmacol       Date:  1977-04       Impact factor: 8.739

7.  Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine.

Authors:  B F Johnson; J LaBrooy; A D Munro-Faure
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

  7 in total
  1 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.